Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Knight Therapeutics Inc (GUD.TO)

Knight Therapeutics Inc (GUD.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Knight Therapeutics Inc 3400 De Maisonneuve West Suite 1055 Montreal QC H3Z 3B8 CAN

https://www.gud-knight.com P: 514-484-4483 F: 514-481-4116

Description:

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.

Key Statistics

Overview:

Market Capitalization, $K 588,812
Shares Outstanding, K 101,170
Annual Sales, $ 328,199 K
Annual Net Income, $ -16,835 K
Last Quarter Sales, $ 74,197 K
Last Quarter Net Income, $ -24,326 K
60-Month Beta 0.29
% of Institutional Shareholders 13.15%

Growth:

1-Year Return 18.67%
3-Year Return 5.93%
5-Year Return -21.86%
5-Year Revenue Growth 92.24%

Per-Share Information:

Latest Earnings Date 05/09/24
Earnings Per Share ttm -0.16
EPS Growth vs. Prev Year -38.46%
Dividend Payout Ratio 0.00%

GUD.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward 97.09
Price/Earnings to Growth N/A
Return-on-Equity % -2.14%
Return-on-Assets % -1.68%
Profit Margin % -5.13%
Debt/Equity 0.07
Price/Sales 1.87
Price/Book 0.79
Book Value/Share 7.38
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar